Roche Gets FDA Approval for Vabysmo as Retinal Vein Occlusion Treatment
27 Outubro 2023 - 2:40AM
Dow Jones News
By Adria Calatayud
Roche Holding said it received approval from the U.S. Food and
Drug Administration for Vabysmo as treatment of macular edema
following retinal vein occlusion, the drug's third indication.
The Swiss pharmaceutical giant said Friday that the approval was
based on two late-stage studies that demonstrated early and
sustained vision improvements.
Vabysmo is already approved for so-called "wet" age-related
macular degeneration and diabetic macular edema, Roche said.
Write to Adria Calatayud at adria.calatayud@dowjones.com
(END) Dow Jones Newswires
October 27, 2023 01:25 ET (05:25 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Roche (QX) (USOTC:RHHBY)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
Notícias em tempo-real sobre Roche Holdings Ltd AG (QX) da OTCMarkets bolsa de valores: 0 artigos recentes
Mais Notícias de Roche Holdings Ltd AG (QX)